Q/C Technologies

TNF-α can help the body defend against disease and infection and is commonly linked to several inflammatory diseases.

Akers Biosciences secures sufficient votes required to consummate the previously announced proposed merger between Akers and MYMD Pharmaceuticals

MyMD Pharmaceuticals was issued a U.S. patent for treating cancers and other disorders associated with chronic inflammation by the United States Patent & Trademark Office (USPTO).

MyMD Pharmaceuticals, Inc. announced that its common shares would begin trading on the NASDAQ Stock Market on April 19 under the ticker symbol MYMD.

Small-cap player Akers Biosciences $AKER has engineered a reverse merger with private company MyMD Pharmaceuticals.

Bill J. White has served as a member of the Board of Directors since August 8, 2017. Mr. White has more than 30 years of experience in financial

Dr. Craig Eagle, MD, is Head of BioOncology for US Medical Affairs at Genentech. Dr. Eagle has a wealth of oncology experience. He joined Pfizer Australia

Ian Rhodes was appointed as Interim Chief Financial Officer on February 1, 2021. Mr. Rhodes joined Brio Financial Group (“Brio”) in January 2021. From

Jeremy Walston, M.D., is the Raymond and Anna Lubin Professor of Geriatric Medicine and Gerontology at the Johns Hopkins University School of Medicine,

TNF Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutic platforms to extend healthy lifespan.

The page invites contact with MyMD about partnership opportunities, proposals, or general questions.

Q/C Technologies is developing a proprietary optical processing unit (OPU) — a silicon photonic computing architecture designed to overcome the bandwidth, energy, and scalability limitations of traditional electronic architectures.

Q/C Technologies is developing a proprietary optical processing unit (OPU) — a silicon photonic computing architecture designed to overcome the bandwidth, energy, and scalability limitations of traditional electronic architectures.

TNF Pharmaceuticals is a clinical-stage biotech pharmaceutical company focused on the development of drug products that target aging and age-related diseases.

MyMD states that it aims to inform visitors about how the website collects and uses their information.

Q/C Technologies partners with Sandia National Laboratories to advance its optical processing unit initiative. The collaboration leverages nanophotonics research at Sandia’s Center to enhance AI inference capabilities. Sandia, a $5 billion U.S. Department of Energy lab, supports this effort through specialized expertise.

Sep 2026Q/C Technologies, Inc.News article

Q/C Technologies appoints Yossef Ehrlichman as Chief Technology Officer. He will oversee the development of an optical processor based on proprietary silicon photonic architecture. The technology aims to address key challenges in AI inference, including bandwidth, energy efficiency, and scalability demands.

Sep 2026Q/C Technologies, Inc.News article

Q/C Technologies hires **Yossef Ehrlichman**, a veteran silicon photonics engineer, as the **Founding Manager of Photonic Integrated Circuit (PIC) Development**. The company specializes in developing advanced photonic solutions for high-speed data transmission and optical computing. Ehrlichman brings decades of expertise in silicon photonics to lead Q/C Technologies’ PIC development efforts.

Aug 2026Q/C Technologies, Inc.News article

Q/C Technologies moves its headquarters to San Francisco to access expertise in photonic computing and optical AI inference. The company establishes an integrated photonics lab to accelerate research and development of its proprietary optical processing unit.

Jun 2026Q/C Technologies, Inc.News article